Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 7/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | CPS1 | P31327 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | P4HB | P07237 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6101478 | 1.00 | HTT (0.37) | HTTKDM4EGHSRARCPS1 | |
| SCHEMBL6959227 | 1.00 | HTT (0.37) | HTTKDM4EGHSRARCPS1 | |
| SCHEMBL6609050 | 0.84 | KDM4E (0.36) | HTTKDM4EARCPS1HTR2A | |
| SCHEMBL6609051 | 0.84 | KDM4E (0.36) | HTTKDM4EARCPS1HTR2A | |
| SCHEMBL6099305 | 0.84 | HTT (0.35) | HTTGHSRARDRD2DRD4 | |
| SCHEMBL6099303 | 0.84 | HTT (0.35) | HTTGHSRARDRD2DRD4 | |
| SCHEMBL6101343 | 0.83 | HTT (0.45) | HTTGHSRARHTR2AHTR2C | |
| SCHEMBL6101340 | 0.83 | HTT (0.45) | HTTGHSRARHTR2AHTR2C | |
| SCHEMBL6100980 | 0.81 | GHSR (0.45) | GHSR | |
| SCHEMBL6100983 | 0.81 | GHSR (0.45) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109201-B2 | Piperazine derivatives, their preparation and uses in therapy | SMITHKLINE BEECHAM PLC (GB) | 2006-09-19 | — | — | US | disclosed |
| EP-1368337-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS 5-HT1B LIGANDS | SMITHKLINE BEECHAM PLC (GB) | 2005-06-15 | — | — | EP | disclosed |
| US-20040142925-A1 | Piperazine derivatives their preparation and uses in therapy | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142925-A1 | Piperazine derivatives their preparation and uses in therapy | NR3C2, NR2C2, NR3C1 | HTT 1367/4885KDM4E 2683/4885GHSR 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.